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Abstract
Background: Programmed necrosis/necroptosis is an emerging form of cell death that plays important roles in mammalian
development and the immune system. The pro-necrotic kinases in the receptor interacting protein (RIP) family are crucial
mediators of programmed necrosis. Recent advances in necrosis research have been greatly aided by the identification of
chemical inhibitors that block programmed necrosis. Necrostatin-1 (Nec-1) and its derivatives were previously shown to
target the pro-necrotic kinase RIP1/RIPK1. The protective effect conferred by Nec-1 and its derivatives in many experimental
model systems was often attributed to the inhibition of RIP1 function.
Methodology/Principal Findings: We compared the effect of Nec-1 and siRNA-mediated silencing of RIP1 in the murine
fibrosarcoma cell line L929. Treatment of L929 cells with the pan-caspase inhibitor zVAD-fmk or exogenous TNF induces
necrosis. Strikingly, we found that siRNA-mediated silencing of RIP1 inhibited zVAD-fmk induced necrosis, but not TNF-
induced necrosis. TNF-induced cell death in RIP1 knocked down L929 cells was inhibited by Nec-1, but not the caspase
inhibitor zVAD-fmk. We found that PKA-C1 expression, but not Jnk or Erk activation, was moderately inhibited by Nec-1.
Moreover, we found that Nec-1 inhibits proximal T cell receptor signaling independent of RIP1, leading to inhibition of T cell
proliferation.
Conclusions/Significance: Our results reveal that besides RIP1, Nec-1 also targets other factors crucial for necrosis induction
in L929 cells. In addition, high doses of Nec-1 inhibit other signal transduction pathways such as that for T cell receptor
activation. These results highlight the importance to independently validate results obtained using Nec-1 with other
approaches such as siRNA-mediated gene silencing. We propose that some of the previous published results obtained using
Nec-1 should be re-evaluated in light of our findings.
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Introduction
Cell death by necrosis is often associated with inflammation.
Although necrosis was once thought to be an un-regulated form of
cell injury due to trauma, recent evidence indicates that necrosis is
a highly regulated process that involves a dedicated molecular
circuitry [1,2]. Specifically, necrosis is the dominant response
when cells are stimulated with TNF-like death cytokines in the
presence of caspase inhibitors [1]. This form of necrosis, often
referred to as programmed necrosis/necroptosis [3], is character-
ized by organelle and cell swelling and eventually plasma
membrane rupture. In necrosis, the loss of plasma membrane
integrity often coincides or precedes the exposure of phosphatidyl
serine [4]. This morphological signature of necrosis distinguishes it
from apoptosis, in which the early exposure of phosphatidyl serine
and other ‘‘eat-me’’ signals prompt their clearance by professional
phagocytes before membrane leakage and release of inflammatory
cellular adjuvants [5]. Thus, necrosis is a more inflammatory form
of cell death than apoptosis.
Recent work shows that the receptor interacting protein (RIP)
kinases RIP1 and RIP3 play essential roles in TNF-induced
necrosis [6,7,8]. In addition to TNF-like death cytokines, RIP1/
RIP3-dependent necrosis also contributes to the abortive embry-
onic development and impaired T lymphocyte proliferation of
FADD2/2 and caspase-82/2 mice [9,10,11,12,13]. Furthermore,
RIP1/RIP3-dependent necrosis has been shown to mediate
cerulein-induced pancreatitis [7,8], retinal detachment induced
photoreceptor necrosis [14], ischemia-induced brain injury [15,16]
and myocardial infarction [17].
Necrostatin-1 (Nec-1) is a small molecule inhibitor originally
identified in a chemical library screen as a potent inhibitor of
TNF-induced necrosis [15]. Subsequent studies show that Nec-1
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specifically inhibits the pro-necrotic kinase function of RIP1 [18],
but has no effects on another pro-necrotic kinase RIP3 [6].
Moreover, Nec-1 does not interfere with TNF-induced NF-kappa
B activation [15], an effect that is also driven by RIP1. Because of
its relatively specific effect against the pro-necrotic activity of
RIP1, Nec-1 has become a popular tool to probe the role of
necrosis in different experimental models of cell injury.
In this report, we show that Nec-1 inhibits necrosis in a RIP1-
independent manner in L929 cells. In addition, at doses that are
commonly used in many studies, Nec-1 impairs the sustained
phosphorylation of linker for activation of T cells (LAT), a crucial
adaptor in proximal T cell receptor (TCR) signaling. As a result,
Nec-1 treated cells failed to expand and proliferate in response to
TCR stimulation. These results reveal that Nec-1 exhibits RIP1-
dependent and independent effects in necrosis and other signal
transduction processes. Thus, care should be taken in interpreting
results derived from using this inhibitor.
Materials and Methods
Ethics Statement
All studies involving animals were approved by the University of
Massachusetts Institutional Animal Care and Use Committee
(IACUC) (protocol #1396). Animals were maintained in accor-
dance with the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, 1996).
Cell death assays
L929 and NIH 3T3 cells (ATCC, Manassas, VA, USA) were
cultured in Dulbecco’s modified Eagle medium. Jurkat cells [19,20]
and primary T cells isolated from wild type and FADD2/2 mice
[21] were cultured in RPMI 1640 medium. All media were
supplemented with 10% fetal bovine serum, 100 units/ml penicillin,
100 mg/ml streptomycin, 30 mg/ml L-glutamine, and 60 mM 2-
mercaptoethanol. For cell death assays, cells were seeded at 5,000–
10,000 cells per well on 96-well microtiter plates and stimulated as
indicated. For L929 and NIH 3T3 cells, 10 ng/ml of recombinant
mouse TNF was used (Invitrogen, Carlsbad, CA, USA). For NIH
3T3 cells were pre-treated with 0.5 mg/ml cycloheximide and
10 mM zVAD-fmk (Axxora, San Diego, CA, USA) for one hour
before TNF stimulation. For Jurkat cells, necrosis was induced by
pretreatment with 20 mM zVAD-fmk for 1 hour and 100 ng/ml
human TNF (Invitrogen, Carlsbad, CA, USA). MAP kinase
inhibitors (Enzo Life Sciences, Farmingdale, NY, USA) were used
at the following concentrations: Erk inhibitor U0126 (50 mM), Jnk
inhibitor II (30 mM), p38 inhibitor SB203580 (50 mM). Cell death
was determined 6–14 hours post-TNF treatment by CellTiter
aqueous non-radioactive cell proliferation assay (MTS) (Promega,
Madison, WI, USA). In some experiments, we confirmed cell death
by flow cytometry using propidium iodide uptake as an indication of
cell death (data not shown).
siRNA transfection
Short oligonucleotide RNAs (27-mer siRNA) were purchased
from IDT technologies (Coralville, IA, USA). For transfection of
siRNA to L929 cells or NIH 3T3 cells, 300,000 cells were seeded
on 6-well plate and transfected with 20 nM siRNA and 12 ml
HiPerfect reagent (Qiagen, Valencia, CA, USA). Thirty-six hours
after transfection, cells were replated on 96-well plate (5,000 cells
per well) overnight before stimulation with recombinant mouse
TNF. siRNA sequences used are: RIP1 #1 (59-gaggauauucucagg-
cuucagguccuu-39), RIP1 #2 (59-ccuucguuuccuuuccuccucucuguu-
39), RIP3 (59-aagauuaaccauagccuucaccuccca-39).
Western blot
Cell lysates or immune complexes were analyzed by standard
SDS-PAGE. After transfer to nitrocellulose membranes, Western
blots were performed with antibodies to RIP1, 1-actin, PARP-1
(BD Pharmingen, San Diego, CA, USA), RIP3 (ProSci, Poway,
CA, USA), Erk, Jnk, PKA substrate (Cell Signaling, Danvers, MA,
USA), PKA, LAT (Santa Cruz, Santa Cruz, CA, USA), and
phospho-tyrosine (Millipore, Bellerica, MA, USA).
Fluorogenic caspase 3 activity assay
Fifty micrograms of cell extracts were diluted in 200 ml of iTFB
buffer (10% sucrose, 30 mM HEPES [pH 7.4], 10 mM CaCl2 and
5 mM DTT) containing 25 mM of N-acetyl-Asp-Glu-Val-Asp-7-
amino-4-methylcoumarin (Ac-DEVD-AMC) (Axxora, San Diego,
CA, USA). The release of fluorescent AMC was measured in a
FLUOSTAR multi-well plate reader at 340 nm for excitation and
450 nm for emission over 3 hours. The rate of conversion was
calculated by including 25 mM of free AMC as control.
T cell activation
CD3+ T cells were purified from the spleens of 10–12 week old
C57BL/6 mice using the Dynal negative T cell isolation kit
(Invitrogen). Flow cytometry shows that the resulting cells were
.98% CD3+ (data not shown). Unless otherwise stated, purified T
cells were stimulated with plate-bound 1 mg/ml anti-CD3 and
200 ng/ml anti-CD28 antibodies (eBioscience, San Diego, CA,
USA). For thymidine incorporation, 1 mCi of [3H]-thymidine was
added to the cells on day 3 for 18 hours before harvesting. For
CellTracer Violet dilution assay, cells were loaded with 5 mM
CellTracer Violet as per manufacturer’s protocol (Invitrogen).
Three days after stimulation, dilution of the dye was determined
on a BD LSR2 flow cytometer and analyzed with Flowjo software
(Treestar, Ashland, OR, USA). For Western blot and immuno-
precipitations of T cell lysates, purified T cells were stimulated
with 3 mg/ml biotinylated anti-CD3 antibody and 0.5 mg/ml
streptavidin for the indicated times before lysis in buffer containing
150 mM NaCl, 20 mM Tris.Cl [pH 7.4], 0.2% NP-40, 1 mM
EDTA, 3 mM NaF, 1 mM b-glycerophosphate, 1 mM sodium
orthovanadate, 10% glycerol, 16 protease inhibitor cocktail
(Roche), and 16 phosphatase inhibitor cocktail (Sigma).
Results
The murine fibrosarcoma L929 cells are unique in that they
readily undergo necrosis in response to TNF [22]. TNF-induced
necrosis in L929 cells did not require caspase inhibition, although
the caspase inhibitor zVAD-fmk did further enhance TNF-
induced necrosis (Fig. 1A). Regardless of whether zVAD-fmk
was used, Nec-1 inhibited TNF-induced necrosis in L929 cells in a
dose-dependent manner, reaching maximal inhibition at 20 mM or
higher (Fig. 1B and data not shown). This dose of Nec-1 (20–
50 mM) was commonly used in many publications [9,15,18,23].
Although Nec-1 has been reported to inhibit the expression of
ectopically expressed RIP1 in HEK293T cells [6], it did not affect
endogenous RIP1 expression in L929 cells (Fig. 1C). These results
are consistent with previous results that Nec-1 is an allosteric
inhibitor of RIP1 kinase function [18].
In addition to exogenous TNF, treatment with the caspase
inhibitor zVAD-fmk alone also causes necrosis in L929 cells [24].
zVAD-fmk induced necrosis in L929 cells is mediated by autocrine
production of TNF. It exhibits a slower kinetics than TNF-induced
necrosis and is optimally induced at high cell density and small
volume of the culture medium [25]. Under these conditions,
siRNA-mediated silencing of RIP1 by two different siRNAs
RIP1-Independent Effects of Necrostatin-1
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efficiently protected L929 cells from zVAD-fmk induced necrosis
(Fig. 2A). This is consistent with previous reports that RIP1 is
required for necrosis induced by zVAD-fmk [24]. Strikingly,
siRNA-mediated silencing of RIP1 had no effects on TNF-induced
necrosis in L929 cells (Fig. 2B). Western blot analysis shows that
the lack of protection against TNF-induced necrosis in L929 cells
Figure 1. Nec-1 inhibits necrosis in L929 cells in a dose-dependent manner. (A) Nec-1 inhibits TNF-induced necrosis in L929 cells. L929 cells
were treated with 10 mM zVAD-fmk, 20 mM Nec-1 and 10 ng/ml mouse TNF (mTNF) as indicated. Cell death was determined by MTS assay as
described in materials and methods. (B) L929 cells were treated with the indicated doses of Nec-1, followed by stimulation with 10 ng/ml mTNF. Cell
Death was analyzed as in (A). (C) Nec-1 did not alter RIP1 or RIP3 protein expression in L929 cells.
doi:10.1371/journal.pone.0023209.g001
Figure 2. Nec-1 inhibits TNF-induced necrosis independent of RIP1 in L929 cells. (A–C) RIP1 is required for zVAD-fmk, but not TNF-induced
necrosis in L929 cells. (A) L929 cells were transfected with the indicated siRNA oligonucleotides with HiPerfect (Qiagen). TR4 is the control siRNA
against TRAIL-R4 [36]. Cells were treated with (A) 50 mM zVAD-fmk or (B) 10 ng/ml mTNF and cell death was measured by MTS assay. (C) Western blot
shows RIP1 and RIP3 expression in cells transfected with the indicated siRNAs. (D–E) RIP1 is required for TNF-induced necrosis in 3T3 fibroblasts. NIH
3T3 fibroblasts were transfected with the indicated siRNA. (D) Expression of RIP1, RIP3 and ß-actin in cells transfected with the indicated siRNA was
determined by Western blot. (E) Necrosis was induced with 10 mM zVAD-fmk, 0.5 mg/ml cycloheximide and 10 ng/ml mTNF for 20 hours. Cell death
was assessed as in (A).
doi:10.1371/journal.pone.0023209.g002
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was not due to inefficient silencing of RIP1 expression (Fig. 2C).
By contrast, similar siRNA-mediated silencing of RIP1 in NIH
3T3 fibroblasts, which was less efficient compared with that
achieved in L929 cells (Fig. 2D), effectively inhibited TNF-induced
necrosis (Fig. 2E). Furthermore, siRNA-mediated silencing of
another essential programmed necrosis mediator, RIP3, effectively
inhibited zVAD-fmk and TNF-induced necrosis in L929 cells
(Fig. 2A–B), and TNF-induced necrosis in NIH 3T3 cells (Fig. 2E).
Our results are consistent with those of Hitomi et al, which show
that siRNA knock-down of RIP1 in L929 cells exhibited disparate
effects on necrosis induced by zVAD-fmk or TNF [26].
Inhibition of the pro-survival transcription factor NF-kappa B
sensitizes cells to TNF-induced apoptosis. Because RIP1 is required
for activation of NF-kappa B, knock-down of RIP1 could have
sensitized L929 cells to TNF-induced apoptosis. In addition, RIP1
competes with TRADD for binding to TNFR1 [27]. Since TRADD
promotes FADD recruitment and apoptosis, loss of RIP1 could
activate caspase-dependent apoptosis. To evaluate this possibility,
we treated RIP1-silenced L929 cells with the pan-caspase inhibitor
zVAD-fmk and/or the RIP1 inhibitor Nec-1. Consistent with
previous results, zVAD-fmk increased TNF-induced necrosis in
RIP1 siRNA (Fig. 3A) and control siRNA transfected cells (Fig. 3B).
In contrast, Nec-1 effectively inhibited TNF-induced necrosis in
RIP1 siRNA (Fig. 3A) and control siRNA transfected cells (Fig. 3B).
Nec-1 also inhibited cell death induced by TNF and zVAD-fmk in
RIP1 siRNA transfected cells (Fig. 3A). Interestingly, residual death
could be detected in RIP1 knock-down L929 cells treated with
TNF, zVAD-fmk, and Nec-1, suggesting the possibility of caspase-
and RIP1-independent cell death under these conditions. PARP-1
cleavage by caspases was not detected in RIP1 siRNA transfected
L929 cells, but was readily detected in TNF-treated Jurkat cells
(Fig. 3C). Furthermore, caspase activity as measured by cleavage of
the fluorogenic peptide substrate DEVD-AMC was not detected in
RIP1 or control siRNA transfected L929 cells, but was readily
detected in TNF-treated Jurkat cells (Fig. 3D). Thus, TNF-induced
necrosis in L929 cells is RIP1-independent and yet inhibitable by
Nec-1.
A recent report indicates that Nec-1 inhibits Erk activation in
TNF and Smac mimetic treated L929 cells [28]. Although the
authors found that Erk inhibition did not protect L929 cells against
TNF/Smac mimetic induced necrosis [28], we found that the Erk
inhibitor U0126 inhibited TNF-induced necrosis in L929 cells,
albeit at a lower level than that by Nec-1 (Fig. 4A). Surprisingly,
phospho-Erk was readily detected in untreated L929 cells, and
TNF treatment led to reduction in phosphorylated Erk (Fig. 4B,
top two panels). By contrast, TNF-induced a transient phosphor-
Figure 3. Knock-down of RIP1 expression in L929 cells did not result in caspase-dependent apoptosis. L929 cells were transfected with
siRNA against (A) RIP1 or (B) TR4. Transfected cells were treated with zVAD-fmk, Nec-1 and TNF as indicated. Cell death was determined by MTS assay.
(C) L929 cells transfected with the indicated siRNA or Jurkat 4E3 cells were treated with TNF. PARP-1 cleavage was determined by Western blot. (D)
Cell lysates from (C) were tested for active caspase 3 as measured by cleavage of the substrate DEVD-AMC. Release of AMC was determined by
increases in AMC fluorescence as described in materials and methods.
doi:10.1371/journal.pone.0023209.g003
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ylation of Jnk1/2 (Fig. 4B, p54 and p46, bottom two panels).
While Nec-1 had no effects on Jnk activation, the reduction of Erk
phosphorylation was more prominent in the presence of Nec-1
(Fig. 4B). To more definitively determine the effect of Nec-1 on
Erk, we tested the effect of Nec-1 in Jurkat cells. TNF and zVAD-
fmk induced necrosis in Jurkat 4E3 cells [19,20], which was
effectively inhibited by the Erk inhibitor U0126 or Nec-1 (Fig. 4C).
By contrast, inhibition of p38 or Jnk had no effects on TNF/
zVAD-fmk induced necrosis in Jurkat 4E3 cells (Fig. 4C). TNF
stimulation did not induce detectable level of Erk phosphorylation
in Jurkat 4E3 cells (data not shown). To evaluate whether Nec-1
inhibits Erk activation in Jurkat cells, we treated the cells with
phorbol myristate acetate (PMA), which strongly induced Erk
phosphorylation. We found that Nec-1 did not inhibit on Erk
phosphorylation in Jurkat 4E3 cells under these conditions
(Fig. 4D). Thus, the effect of Nec-1 on Erk phosphorylation in
L929 cells is likely due to inhibition of RIP1, which is required for
downstream Erk activation in certain cells [29].
A recent report indicates that Nec-1 could inhibit PKA activity
in vitro [30]. Interestingly, we previously identified PKA-C1 as a
Figure 4. Effects of Nec-1 on Jnk, Erk and PKA-Cb. (A) L929 cells were treated with TNF in the presence of 20 mM Nec-1 or 50 mM of the Erk
inhibitor U0126. Cell death was determined by MTS assay. (B) The effect of Nec-1 on Erk or Jnk phosphorylation. L929 cells treated with 10 ng/ml of
mTNF in the presence or absence of 30 mM Nec-1 were analyzed for Erk activation (p-p54 and p-p46) or Jnk activation by Western blot. (C) Erk
inhibitor U0126 and Nec-1 blocks TNF-induced necrosis in Jurkat cells. Jurkat 4E3 cells [20] were treated with Erk inhibitor (50 mM U0126), Jnk
inhibitor (30 mM Jnk inhibitor II), p38 inhibitor (50 mM SB203580), or 10 mM Nec-1 and stimulated with 100 ng/ml recombinant human TNF plus
10 mM zVAD-fmk for 14 hours. Cell death was determined by MTS assay. (D) Jurkat 4E3 cells were stimulated with 10 ng/ml PMA for 10 minutes in the
presence of 30 mM Nec-1 or 50 mM U0126. Phospho-Erk was examined by Western blot as indicated. (E) Jurkat 4E3 cells were treated with the
indicated doses of Nec-1 and 100 nM calyculin A. The expression of the two different PKA isoforms and phosphorylation of protein kinase A
substrates was determined by Western blot with specific mantibodies as described in materials and methods.
doi:10.1371/journal.pone.0023209.g004
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putative necrosis regulator in a RNA interference screen [6]. We
therefore tested whether Nec-1 might affect PKA functions.
Treatment of Jurkat 4E3 cells with Nec-1 led to reduced
expression of PKA-C1 in a dose-dependent manner (Fig. 4E,
lower panel). Although Nec-1 had minimal effects on calyculin A
induced phosphorylation of PKA substrates (Fig. 4E, top panel),
this could be due to the compensatory effects of PKA-Ca and
other calyculin A sensitive kinases. Thus, PKA-C1 might be one of
the RIP independent targets of Nec-1.
In addition to inhibiting TNF-induced necrosis, Nec-1 has also
been shown to rescue necrosis in caspase-82/2 [9] and FADD2/2
T cells [23] in response to T cell receptor (TCR) stimulation.
Indeed, low doses of Nec-1 (,1 mM) were sufficient to inhibit
necrosis and rescue defective proliferation of FADD2/2 T cells
(Fig. 5A) [31]. Strikingly, we found that higher doses of Nec-1
(.20 mM) led to reduced proliferation of wild type and FADD2/2
T cells in a dose-dependent manner (Fig. 5A). The inhibition of T
cell proliferation by high doses of Nec-1 might be due to inhibition
of cell proliferation or increased cytotoxicity. Incubation of naı¨ve
T cells in vitro without stimulation led to cell death by neglect.
Consistently, the viability of untreated T cells 24 hours later was
reduced to ,60% (Fig. 5B, left panel). Incubation of these naı¨ve T
cells with 50 mM of Nec-1 did not further reduce the cell viability
(Fig. 5B, right panel). Thus, the inhibitory effect of Nec-1 on T cell
proliferation was not due to toxicity of the inhibitor.
We next measured T cell proliferation by labeling cells with the
fluorescent dye CellTracer Violet. CellTracer Violet partitions
equally between daughter cells as the parent cell undergoes cell
division. Thus, the reduction in fluorescence signal indicates the
number of cell divisions the cells have undergone. Treatment of
Figure 5. High doses of Nec-1 inhibit T cell proliferation. (A) Low dose Nec-1 inhibits TCR-induced necrosis, but high dose Nec-1 inhibits T cell
proliferation. Purified T cells from wild type or FADD2/2 mice were stimulated with plate-bound anti-CD3, anti-CD28 and increasing doses of Nec-1.
Three days later, cell proliferation was measured by incorporation of [3H]-thymidine. Results shown are mean 6 SEM. (B) Nec-1 did not compromised
T cell viability. Naı¨ve CD3+ T cells were purified from the spleen of wild type C57BL/6 mice and incubated at 37uC for 24 hours in the presence or
absence of 50 mM Nec-1. Viability of the cells was determined by flow cytometry using propidium iodide (PI) uptake as an indication of cell death.
Note that Nec-1 increased the baseline fluorescence of the T cells. (C) Nec-1 inhibits T cell division. Purified CD3+ primary T cells were labeled with
CellTracer Violet fluorescent dye and stimulated with 1 mg/ml plate-bound anti-CD3 and 200 ng/ml anti-CD28 antibodies. Three days later, cell
division was analyzed using a BD LSR2 flow cytometer. The numbers above each peak represent the number of cell division the cells had undergone.
The numbers on the left represent the percentages of cells in each peak. (D) Nec-1 inhibits T cell blast formation. Purified CD3+ T cells were similarly
activated as in (C). Three days later, formation of T cell blast as measured by forward scatter was determined by flow cytometry. (E) FADD2/2RIP12/2
DKO T cells stimulated with plate-bound anti-CD3 and anti-CD28 antibodies in the absence or presence of Nec-1 were measured for cell proliferation
as in (C).
doi:10.1371/journal.pone.0023209.g005
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purified murine CD3+ T cells with plate-bound anti-CD3
antibody, which mimics TCR signaling, and the costimulatory
molecule CD28 potently stimulated cell proliferation as shown by
the dilution of the CellTracer Violet dye (Fig. 5C, panel a). At
doses that are commonly used in other studies (30 mM), Nec-1
severely impeded cell division (Fig. 5C, compare panels a and e).
In fact, cell division was completely abrogated by 50 mM of Nec-1
(Fig. 5C, panel f). Importantly, lower doses of Nec-1 (1 mM) that
were sufficient to inhibit FADD2/2 T cell necrosis had little effect
on T cell division (Fig. 5C, panel b). In addition to cell
proliferation, T cell activation also leads to increase in cell size,
which can be measured as an increase in forward light scatter by
flow cytometry. Consistent with the cell proliferation results, Nec-1
inhibited the formation of ‘‘T cell blasts’’ in response to TCR/
CD28 stimulation in a dose-dependent manner (Fig. 5D).
RIP12/2 T cells exhibit a modest defect in T cell proliferation
[32]. Thus, the effect of Nec-1 on T cell proliferation could be due
to inhibition of RIP1. To evaluate this possibility, we examined the
effect of Nec-1 on FADD2/2RIP12/2 double knock-out (DKO)
T cells. Unlike the FADD2/2 or RIP12/2 T cells, the DKO T
cells exhibited normal T cell proliferation [10]. We found that
proliferation of DKO T cells was similarly inhibited by high doses
of Nec-1 (Fig. 5E). Taken together, these results indicate that Nec-
1 inhibits T cell proliferation independent of RIP1.
The effect of Nec-1 on T cell proliferation suggests that it might
target proximal signaling of the TCR. A signature of proximal
TCR signaling is the rapid phosphorylation at tyrosine residues for
many adaptor proteins and kinases. Western blot with phospho-
tyrosine antibody showed that the phosphorylation of several
protein species was differentially affected by Nec-1. In particular,
the TCR-induced phosphorylation of a 30–40 kDa species that
resembled the size of the essential adaptor LAT (linker for
activation of T cells) was visibly reduced by Nec-1 (Fig. 6A, right
panel). To confirm the effect of Nec-1 on LAT phosphorylation,
we immunoprecipitated the T cell lysates with the phospho-
tyrosine antibody, followed by Western blot analysis of LAT. We
found that while Nec-1 did not dramatically affect the initial
phosphorylation of LAT, it abolished sustained LAT phosphor-
ylation (Fig. 6B, compare lanes 3 and 6). In contrast, phosphor-
ylation of Lck, an upstream tyrosine kinase that is phosphorylated
at the inhibitory tyrosine Y505 before TCR activation and Y394
after TCR stimulation [33], was not affected by Nec-1 (Fig. 6B).
Furthermore, phosphorylation of Erk was not diminished by Nec-
1 (Fig. 6C). Thus, we conclude that the abrogation of LAT
phosphorylation is one of the possible mechanisms by which Nec-1
inhibits T cell proliferation.
Discussion
The emerging role of RIP1 and RIP3-dependent necrosis in
many disease pathologies have led to the wide use of Nec-1 and its
derivatives by many investigators. Nec-1 was thought to
specifically inhibit the pro-necrotic kinase function of RIP1
[15,18] without affecting the kinase activity of RIP3 [6]. In this
report, we show that Nec-1 exhibits an unexpected anti-necrotic
effect that is independent of RIP1. In L929 cells, necrosis could be
induced by treatment with zVAD-fmk or exogenous TNF.
However, our data indicated that zVAD-fmk induced necrosis,
but not TNF-induced necrosis, was dependent on RIP1. This is
surprising because a recent report shows that zVAD-fmk triggers
autocrine TNF production that in turn activates necrosis
downstream of TNFR1 [25]. The requirement for RIP1 in
zVAD-fmk induced necrosis might be explained by its effect on
MAP kinase activation [29]. Furthermore, a recent report shows
that zVAD-fmk activated a PKC-MAPK signaling axis that is
responsible for autocrine production of TNF in L929 cells [25].
Thus, we speculate that the requirement for RIP1 in zVAD-fmk
induced necrosis might be attributed to its role in MAP kinase
induced TNF production.
In addition to TNF-induced necrosis in L929 cells, it is
noteworthy that RIP1-independent but RIP3-dependent necrosis
has also been observed in murine cytomegalovirus (MCMV)
infection [34]. Therefore, although RIP1 is the upstream activator
of RIP3 in most cases, necrosis can proceed in a RIP1-
independent manner. Whether RIP3 acts alone or in concert
with another RIP1-like factor in these situations will be the subject
of further investigation. Importantly, the death of L929 cells with
knocked-down expression of RIP1 was inhibited by Nec-1, but not
zVAD-fmk. This result rules out the possibility of conversion of
necrosis to apoptosis upon RIP1 silencing. While these results
Figure 6. Nec-1 blocks sustained phosphorylation of LAT during T cell activation. (A) Whole cell extracts (WCE) were examined from T cells
stimulated with anti-CD3 antibody in the presence or absence of 50 mM Nec-1. Western blot was performed with phospho-tyrosine specific antibody.
Short and long exposures were shown to highlight the different phosphorylated species. (B) Nec-1 impairs TCR-induced LAT phosphorylation. Total
lysates from activated T cells were subjected to immunoprecipitation with phospho-tyrosine antibody. The resulting immune complex was evaluated
for presence of LAT and Lck by Western blot. (C) Nec-1 does not affect Erk phosphorylation. Purified T cells were stimulated as in (A). Western blot was
performed with phospo-Erk or total Erk specific antibodies.
doi:10.1371/journal.pone.0023209.g006
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could be explained by incomplete silencing of RIP1, it is unlikely
because zVAD-fmk induced necrosis was efficiently inhibited in
the same cells. Interestingly, residual death could be detected in
RIP1-silenced L929 cells treated with TNF, zVAD-fmk and Nec-
1. This result suggests the possibility that caspase- and RIP1-
independent cell death might occur when both apoptosis and
necrosis pathways are inhibited.
Nec-1 modestly reduced expression of PKA-C1, but had little
effects on Jnk or Erk activation. The effect of Nec-1 on PKA-C1 is
intriguing because PKA-C1 was identified as a putative necrosis
mediator previously [6,35]. Based on our findings, the anti-
necrosis effect of Nec-1 previously attributed to RIP1 might have
to be re-evaluated. Interestingly, low doses of Nec-1 (1 mM) were
sufficient to rescue necrosis in FADD2/2 T cells. In contrast,
higher doses of Nec-1 (20 mM) were required to fully rescue TNF-
induced necrosis in L929 cells. The molecular basis for this
differential sensitivity to Nec-1 is unknown, but could be due to
different RIP1 expression level or Nec-1 inhibition of other
necrosis mediators in L929 cells.
Besides its effect on necrosis, Nec-1 also interferes with proximal
TCR signaling. Importantly, the inhibition of TCR signaling and
proliferation was only apparent at higher concentrations of Nec-1
that were commonly used in studies assessing the role of RIP1-
dependent necrosis in different cells [9,23]. Nec-1 mediated
inhibition of T cell proliferation was not reported in these studies.
However, we have observed similar inhibition of T cell
proliferation by Nec-1 using different batches of Nec-1 from
different vendors (data not shown). Since high dose of Nec-1 had
no effect on cell viability, the inhibitory effect of Nec-1 could not
be attributed to drug toxicity. Because the full effect of Nec-1 on T
cell proliferation required pre-incubation of cells for 1 hour, the
discrepant results could be attributed to subtle differences in
culture conditions used in the different studies.
Nec-1 blunted sustained phosphorylation of the essential TCR
signal adaptor LAT. Interestingly, the initial activation of LAT
and the downstream kinase Erk was not affected. Although it is
speculative, our results suggest that Nec-1 might stimulate the
dephosphorylation of LAT.
In summary, our results highlight the fact that while it is a
powerful inhibitor of RIP1, Nec-1 could interfere with the
functions of other signaling proteins. We suggest that the dosage
of Nec-1 should be carefully titrated in each cell type to determine
the minimal dose required for inhibition of necrosis to minimize
off-target effects. These results also suggest that results obtained
using Nec-1 should be independently confirmed using other
approaches such as RNA interference-mediated gene silencing.
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